Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group.

摘要: Aim:  The aim of the present study was to investigate association between length treatment period and cumulative dose pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) their effectiveness in chronic hepatitis C. Methods:  Seven hundred fifteen patients received peg-IFN RBV for 48 weeks 24 weeks genotypes 1 (n = 586) 2 (n = 129), respectively. Results:  Sustained virological responses (SVR), defined as serum C virus (HCV)-RNA undetectable at after end treatment, were 42.4% 74.4% 2, respectively, on an intention-to-treat analysis. SVR significantly increased with (4.7%, 36.4%, 51.8% < 24 weeks, 24–47 weeks, 48 weeks, genotype 1; 28.6%, 57.1%, 78.3% < 12 weeks, 12–23 weeks, 24 weeks, 2). total (21.1%, 36.5%, 52.9% < 60%, 60–79%, ≥ 80% dose; 29.6%, 51.1%, 59.2% dose) 1, although it did not differ 2. Conclusions:  In C, is important complete target continue dosage achieve SVR, especially patients.